vimarsana.com

ஐயுவா நகரம் வீரர்கள் வாழ்க்கைத்தொழில்கள் ஆரோக்கியம் பராமரிப்பு அமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Large Remdesivir Study Finds No COVID-19 Survival Benefit

Large Remdesivir Study Finds No COVID-19 Survival Benefit July 16, 2021 A lack of consensus regarding the antiviral drug remdesivir to treat people with COVID-19 continues, leaving doctors without clear direction on one of the few treatments for the illness the FDA has granted emergency use authorization. The latest research comes from Michael Ohl, MD, and colleagues who studied a large group of Veterans Administration patients hospitalized with COVID-19. Compared with a matched group of veterans who did not receive the antiviral, remdesivir did not significantly improve survival rates The percentages were close: 12.2% of patients in the remdesivir group died within 30 days compared to 10.6% of those in the control group.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.